Athira pharma announces topline results from phase 2/3 lift-ad clinical trial of fosgonimeton for mild-to-moderate alzheimer's disease

Lift-ad trial did not meet primary endpoint of gst and key secondary endpoints of cognition (adas-cog11) and function (adcs-adl23)
ATHA Ratings Summary
ATHA Quant Ranking